A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topical Ocular DS101 in Healthy Subjects

The primary objective of this clinical trial is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of the topical ocular administration of DS101 in healthy subjects. This is a Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group study. The clinical relevance of this study lies in its potential to inform future research and therapeutic strategies for conditions such as **diabetic retinopathy**. No secondary objectives are specified for this trial.

The clinical trial focuses on **diabetic retinopathy** and includes both male and female participants. The study population comprises individuals within the age ranges of 18 to 64 years. Participants are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed. The selection process for the trial population remains unspecified.

The clinical trial is a **Phase I**, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability, and pharmacokinetics of topical ocular administration of DS101 in healthy subjects. The trial targets individuals with **diabetic retinopathy** and is scheduled to commence recruitment on July 15, 2025, with an estimated completion date of February 5, 2026. The study involves a series of structured visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants will undergo randomization to receive either the investigational product or a placebo in a double-blind manner, ensuring that neither the participants nor the investigators are aware of the treatment assignments.

Throughout the trial, participants will attend multiple follow-up visits to monitor safety and collect pharmacokinetic data. These visits are crucial for assessing the drug's effects and any adverse reactions. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to ensure participant safety and gather comprehensive data on the investigational product's performance. The expected duration of participant involvement is contingent upon the dosing schedule and follow-up requirements, with the possibility of early termination if safety concerns arise or if the participant withdraws consent. The trial's design and procedures are meticulously structured to ensure the integrity of the data collected and the safety of all participants involved.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess the efficacy of an investigational product in a Phase 1 setting. The trial is scheduled to commence recruitment on July 15, 2025, with an estimated completion date of February 5, 2026. The primary and secondary endpoints for evaluating efficacy have not been specified in the available data. The trial will follow standard procedures for Phase 1 trials, focusing on initial safety and efficacy assessments. The specific methods and tools for measuring efficacy parameters, as well as the schedule for data collection and analysis, are not detailed in the provided information. The trial will adhere to regulatory guidelines and ethical standards to ensure the integrity and reliability of the efficacy data collected.